Evidence map›Paper›PMID 36000843›Full record

ArticleJournal of virology2022

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.

Sabari Nath Neerukonda, Richard Wang, Russell Vassell, Haseebullah Baha, Sabrina Lusvarghi, Shufeng Liu, Tony Wang, Carol D Weiss, Wei Wang

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sabari Nath NeerukondaUS Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation, Research and Review, Silver Spring, Maryland, USA.
Richard WangUS Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation, Research and Review, Silver Spring, Maryland, USA.
Russell VassellUS Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation, Research and Review, Silver Spring, Maryland, USA.
Haseebullah BahaUS Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation, Research and Review, Silver Spring, Maryland, USA.
Sabrina LusvarghiUS Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation, Research and Review, Silver Spring, Maryland, USA.
Shufeng LiuUS Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation, Research and Review, Silver Spring, Maryland, USA.ORCID 0000-0001-9969-6041
Tony WangUS Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation, Research and Review, Silver Spring, Maryland, USA.ORCID 0000-0001-8983-1721
Carol D WeissUS Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation, Research and Review, Silver Spring, Maryland, USA.ORCID 0000-0002-9965-1289
Wei WangUS Food and Drug Administration, Office of Vaccine Research and Review, Center for Biologics Evaluation, Research and Review, Silver Spring, Maryland, USA.ORCID 0000-0003-2935-6388
Center for Biologics Evaluation and Research · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 Omicron variants were first detected in November 2021, and several Omicron lineages (BA.1, BA.2, BA.3, BA.4, and BA.5) have since rapidly emerged. Studies characterizing the mechanisms of Omicron variant infection and sensitivity to neutralizing antibodies induced upon vaccination are ongoing by several groups. In the present study, we used pseudoviruses to show that the transmembrane serine protease 2 (TMPRSS2) enhances infection of BA.1, BA.1.1, BA.2, and BA.3 Omicron variants to a lesser extent than ancestral D614G. We further show that Omicron variants have higher sensitivity to inhibition by soluble angiotensin-converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared to D614G. The Omicron variants also more efficiently used ACE2 receptors from 9 out of 10 animal species tested, and unlike the D614G variant, used mouse ACE2 due to the Q493R and Q498R spike substitutions. Finally, neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7- to 8-fold less potent than the D614G. These results provide insights into the transmissibility and immune evasion capacity of the emerging Omicron variants to curb their ongoing spread.

Indexed as

Angiotensin-Converting Enzyme 2Antibodies, NeutralizingCOVID-19Immune EvasionSARS-CoV-2Virus InternalizationAnimalsAntibodies, ViralBNT162 VaccineHumansMiceSpecies SpecificitySpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2animal ACE2 receptorsbreakthrough infectionsneutralization resistanceSARS-CoV-2 Omicron variantstransmembrane serine protease 2vaccine boostervirus entry pathways

Identifiers

PMID36000843
PMCPMC9472608
OpenAlexW4293212486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.